Outset Medical, Inc. $OM Shares Sold by National Bank of Canada FI

Key Points

• National Bank of Canada FI significantly reduced its stake in Outset Medical by 64.8%, now holding about 0.49% of the company worth $195,000 after selling 32,442 shares.
• Several hedge funds have recently increased their positions in Outset Medical, with Birchview Capital LP notably raising its stake by 3,587.7%, acquiring 368,766 shares.
• Analysts have varied outlooks on Outset Medical, with some firms setting target prices as high as $37.00 and rating the stock from "sell" to "strong-buy."

National Bank of Canada FI lowered its stake in shares of Outset Medical, Inc. (NASDAQ:OM - Free Report) by 64.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,602 shares of the company's stock after selling 32,442 shares during the quarter. National Bank of Canada FI owned about 0.49% of Outset Medical worth $195,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Two Sigma Securities LLC boosted its position in Outset Medical by 190.0% in the 4th quarter. Two Sigma Securities LLC now owns 42,477 shares of the company's stock worth $47,000 after purchasing an additional 27,830 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Outset Medical during the 4th quarter worth approximately $50,000. Squarepoint Ops LLC acquired a new position in shares of Outset Medical during the 4th quarter worth approximately $174,000. Birchview Capital LP raised its stake in shares of Outset Medical by 3,587.7% during the 4th quarter. Birchview Capital LP now owns 368,766 shares of the company's stock worth $409,000 after buying an additional 358,766 shares during the period. Finally, Two Sigma Investments LP raised its stake in shares of Outset Medical by 36.0% during the 4th quarter. Two Sigma Investments LP now owns 488,602 shares of the company's stock worth $542,000 after buying an additional 129,334 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on OM shares. BTIG Research set a $37.00 target price on Outset Medical and gave the stock a "buy" rating in a research note on Monday, July 14th. Wall Street Zen raised Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Scotiabank raised Outset Medical to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Royal Bank Of Canada lifted their target price on shares of Outset Medical from $21.00 to $22.00 and gave the stock a "sector perform" rating in a research note on Thursday, August 7th.

Outset Medical Stock Performance

OM opened at $13.29 on Monday. The firm has a market capitalization of $236.16 million, a PE ratio of -0.65 and a beta of 2.14. Outset Medical, Inc. has a twelve month low of $5.85 and a twelve month high of $25.35. The firm's 50-day moving average price is $17.97 and its 200 day moving average price is $14.59. The company has a current ratio of 7.47, a quick ratio of 6.05 and a debt-to-equity ratio of 0.63.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.